(NASDAQ: COCP) Cocrystal Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.82%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.6%.
Cocrystal Pharma's earnings in 2025 is -$12,561,000.On average, 3 Wall Street analysts forecast COCP's earnings for 2025 to be -$10,908,252, with the lowest COCP earnings forecast at -$15,183,122, and the highest COCP earnings forecast at -$8,720,036. On average, 2 Wall Street analysts forecast COCP's earnings for 2026 to be -$11,900,285, with the lowest COCP earnings forecast at -$14,567,590, and the highest COCP earnings forecast at -$9,232,979.
In 2027, COCP is forecast to generate -$12,310,639 in earnings, with the lowest earnings forecast at -$12,310,639 and the highest earnings forecast at -$12,310,639.